Cancer drugs price rise 'costing NHS millions'

Cancer drugs price rise 'costing NHS millions' Some cancer drugs that are no longer under patent are rising in price when they should be falling. UK prices for generic cancer drugs have risen sharply in the past five years, restricting their use in treating NHS patients, research from the European Cancer Congress has found. Drugs such as tamoxifen and bulsufan are now 10 times more expensive despite no longer being under patent. BBC News